A novel class of inhibitors for human steroid 5α-reductase: Synthesis and biological evaluation of indole derivatives. II

Chemical and Pharmaceutical Bulletin

Volumn 48, Issue 3, 2000, Pages 382-388

  Igarashi, Susumu ^a   Inami, Hiroshi ^a   Hara, Hiromu ^a   Fujii, Masahiro ^a   Koutoku, Hiroshi ^a   Oritani, Hiroyuki ^a,b   Mase, Toshiyasu ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b INSTITUTE FOR DEVELOPMENTAL RESEARCH   (Japan)

Author keywords

5 reductase inhibitor; Benign prostatic hypertrophy; Indole derivative; YM 32906

Indexed keywords

3 CHLORO 4 [[1 (4 PHENOXYBENZYL) 1H INDOL 5 YL]OXY]BENZOIC ACID; 4 [(1 BENZYL 1H INDOL 5 YL)OXY] 3 CHLOROBENZOIC ACID; FINASTERIDE; INDOLE DERIVATIVE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RAT; STRUCTURE ACTIVITY RELATION;

EID: 0034071008     PISSN: 00092363     EISSN: None     Source Type: Journal    
DOI: 10.1248/cpb.48.382     Document Type: Article

References (27)

1. Igarashi S., Kimura T., Naito R., Hara H, Fujii M., Koutoku H., Oritani H., Mase T., Chem. Pharm. Bull., 47, 1073-1080 (1999).
2. a) Metcalf B. W., Levy M. A., Holt D. A., Trends Pharmacol. Sci., 10, 491-495 (1989);
3. b) Adachi K., Kano M., Biochem. Biophys. Res. Comm., 41, 884-890 (1970);
4. c) Books J. R., J. Clin. Endocrinol. Metab., 74, 391-405 (1986).
5. Recent studies on steroidal 5α-reductase inhibitors: a) Rasmusson G. H., Reynolds G. F., Steinberg N. G., Walton E., Patel G. F., Liang T., Cascieri M. A., Cheung A. H., Brooks J. R., Berman C., J. Med. Chem., 29, 2298-2315 (1986);
6. b) Metcalf B. W., Holt D. A., Levy M. A., Erb J. M., Heaslip J. I., Brandt M, Oh H.-J., Bioorg. Chem., 17, 372-376 (1989);
7. c) Holt D. A., Levy M. A., Ladd D. L., Oh H.-J., Erb J. M., Heaslip J. I., Brandt M., Metcalf B. W., J. Med. Chem., 33, 937-942 (1990);
8. d) Holt D. A., Levy M. A., Oh H.-J., Erb J. M., Heaslip J. I., Brandt M., Lan-Hargest H.-Y., Metcalf B. W., ibid., 33, 943-950 (1990);
9. e) Levy M. A., Metcalf B. W., Brandt M., Erb J. M., Oh H.-J., Heaslip J. I., Yen H.-K., Rozamus L. W., Holt D. A., Bioorg. Chem., 19, 245-260 (1991);
10. f) Bakshi R. K., Patel G. F., Rasmusson G. H., Baginsky W. F., Cimis G., Ellsworth K., Chang B., Bull H., Tolman R. L., Harris G. S., J. Med. Chem., 37, 3871-3874 (1994);
11. g) Li X., Singh S. M., Cote J., Laplante S., Veilleux R., Labrie F., ibid., 38, 1456-1461 (1995);
12. h) Frye S. V., Haffner C. D., Maloney P. R., Hinter R. N., Dorsey G. F., Noe R. A., Unwalla R. J., Batchelor K. W., Bramson H. N., Stuart J. D., Schweiker S. L., Arnold J. V., Bickett D. M., Moss M. L., Tian G., Lee F. W., Tippin T. K., James M. K., Grizzle M. K., Long J. E., Croom D. K., ibid., 38, 2621-2627 (1995);
13. i) Hausler A., Allegrini P. R., Biollaz M., Batzl C., Scheidegger E., Bhatnagar A. S., J. Steroid Biochem. Mol. Biol., 57, 187-195 (1996).
14. Recent studies on nonsteroidal 5α-reductase inhibitors: a) Nakai H., Terajima H., Arai Y., Eur. Patent Appl., EP 291245 [Chem. Abstr., 110, 212384t (1989)];
15. b) Jones C. D., Audia J. E., Lawhorn D. E., McQuaid L. A., Neubauer B. L., Pike A. J., Pennington P. A., Stamm N. B., Toomey R. E., Hirsch K. S., J. Med Chem., 36, 421-423 (1993);
16. c) Holt D. A., Yamashita D. S., Konialian-Beak A. L., Luengo J. I., Abell A. D., Bergsma D. J., Brandt M., Levy M. A., ibid., 38, 13-15 (1995);
17. d) Blagg J., Ballard S. A., Cooper K., Finn P. W., Johnson P. S., MacIntyre F., Maw G. N., Spargo P. L., Bioorg. Med Chem. Lett., 6, 1517-1522 (1996);
18. e) Takami H., Koshimura H., Kishibayashi N., Ishii A., Nonaka H., Aoyama S., Kase H., Kumazawa T., J. Med. Chem., 39, 5047-5052 (1996);
19. f) Kato M., Komada K., Namera A., Sakai Y., Okada S., Yamada A., Yokoyama K., Migita E., Minobe Y., Tani T., Chem. Pharm. Bull., 45, 1767-1776 (1997).
20. Andersson S., Russell D. W., Proc. Natl. Acad. Sci. U.S.A., 87, 3640-3644 (1990).
21. Moore R. J., Wilson J. D., J. Biol. Chem., 251, 5895-5900 (1976).
22. Andersson S., Berman D. M., Jenkins E. P., Russell D. W., Nature (London), 354, 159-161 (1991).
23. Rittmaster R.S., N. Engl. J. Med., 330, 120-125 (1994).
24. The inhibitory activities of finasteride and (±)-ONO-3805 for human prostatic 5α-reductase were evaluated in our company. The results are described in Table 4.
25. Heaney H., Ley S. V., J. Chem. Soc., Perkin Trans. 1, 1973, 499-500.
26. Giudici D., Briatico G., Cominato C., Zaccheo T., Iehle C., Nesi M., Panzeri A., di Salle E., J. Steroid Biochem. Mol. Biol., 58, 299-305 (1996).
27. Liang T., Cascieri M. A., Cheung A. H., Reynolds C. F., Rasmusson G. H., Endocrinology, 117, 571-579 (1985).